SCENESSE® secures Health Canada approval, opening a fourth market for CLINUVEL’s EPP therapy
CLINUVEL Pharmaceuticals has secured a Notice of Compliance (NOC) from Health Canada for SCENESSE® (afamelanotide), authorising the drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Announced on 13 July 2026, the approval makes Canada the fourth market to authorise the therapy, following Europe (2014), the U.S.A. (2019) and Australia (2020).
The NOC acknowledges compliance of the SCENESSE® new drug submission with Section C.08.002 and C.08.005 of the Canadian Food and Drug Regulations, granting CLINUVEL the right to market SCENESSE® in Canada. For a company whose SCENESSE® therapy is the only approved treatment for EPP worldwide, the decision extends its footprint into a new national market where treatment infrastructure is already in place.
When big ASX news breaks, our subscribers know first
A market already primed: five accredited Centers ready to treat
The Canadian approval does not require CLINUVEL to build a market from scratch. The company has established a network of Specialty Centers across North America to treat EPP patients since the drug’s approval by the U.S. Food and Drug Administration in 2019.
In Canada specifically, five Centers are already trained and accredited and have treated EPP patients with SCENESSE® under special access arrangements. This existing capacity connects directly to the broader North American network, meaning patient identification and clinical delivery pathways are already operational.
The global approval sequence now reads:
- Europe — 2014
- U.S.A. — 2019
- Australia — 2020
- Canada — 2026
Dr Dennis Wright, Chief Scientific Officer
“Health Canada has taken a long time to arrive at this positive outcome. Data from our global programs – including considerable data from postmarketing experience – were used to demonstrate the safety and clinical benefit of SCENESSE® in EPP, where the mechanism of action is well understood. The major benefit of the drug is its proven long-term and consistent safety profile. Other drugs in development for EPP lack these data.”
“I thank our team for this momentous outcome and their tenacity for ensuring eligible patients may get access to this therapy.”
What is EPP, and why SCENESSE® matters
Erythropoietic protoporphyria (EPP) is a rare metabolic disorder that causes debilitating phototoxic reactions and burns following brief exposure to visible light, particularly sunlight.
SCENESSE® contains 16mg of the peptide afamelanotide, an analogue of a naturally occurring hormone that stimulates the production of melanin in skin. The drug provides a photoprotective effect, preventing the penetration of light through skin while also acting as a strong antioxidant.
Its commercial significance rests on a differentiated regulatory position: SCENESSE® is the only treatment for EPP to have received marketing authorisation from any regulatory body worldwide, recognising the drug’s clinical benefit, safety and quality.
Key data points supporting the therapy include:
- EPP is estimated to affect 5,000–10,000 individuals globally
- Approximately 1 in 140,000 individuals in Canada
- Over 21,000 doses administered to EPP patients worldwide
- Longest-treated patients receiving up to 20 years of continuous therapy under expert care
The investment case: a differentiated, hard-to-replicate franchise
CLINUVEL is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening conditions. The Canadian approval sits within this thesis as an incremental expansion of an already authorised product into a fourth developed market.
CLINUVEL’s record revenues and profitability streak of 9.5 consecutive years, backed by a debt-free balance sheet carrying $233 million in cash, provide the self-funding capacity that makes multi-market regulatory campaigns like the Canadian approval financially sustainable without shareholder dilution.
The competitive positioning centres on data. SCENESSE® remains the only authorised EPP treatment globally, and Dr Dennis Wright, Chief Scientific Officer has noted that “other drugs in development for EPP lack these data,” referring to the drug’s real-world, long-term safety record accumulated across two decades of use.
| Fact |
|---|
| Health Canada NOC granted |
| Five accredited Canadian Centers already treating |
| Only authorised EPP therapy worldwide |
| 21,000+ doses, up to 20 years of data |
Next steps: from approval to Canadian market activation
With the NOC in place, the immediate pathway runs through the five accredited Canadian Centers already treating EPP patients. These sites provide the clinical channel through which commercial treatment can proceed.
The announcement does not disclose any Canadian revenue forecast, pricing, or reimbursement detail, and no launch timeline was provided. The strategic significance lies in the methodical expansion of SCENESSE®’s authorised markets, adding a fourth market to a portfolio built around the world’s only approved EPP therapy.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button to start receiving real-time coverage today.